06:21 AM EDT, 07/11/2024 (MT Newswires) -- Biogen (BIIB) and Eisai said Thursday that the Alzheimer's disease drug Leqembi has been approved by Hong Kong's Department of Health.

The approval was based on a late-stage trial that met its primary endpoint and all key secondary endpoints, the companies said.

Eisai leads the drug's development and regulatory activities, and will be in charge for distribution in Hong Kong, while Biogen co-commercializes the product.

Price: 232.70, Change: -0.05, Percent Change: -0.02